The first children have been treated in the younger age group of the ProTrans-Young study

October 1, 2024

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), announces that the first four children in the 7–11 year age group have been treated in the latest phase of the ProTrans-Young study. An additional four children have been screened and are expected to begin their treatment shortly. These advancements mark an important milestone in the progress of the study, which is proceeding faster than anticipated.

“There is a high level of interest in the study, and many are signing up from all over the country,” comments Karin Kjellström, research nurse at Uppsala University Hospital. The study aims to evaluate the efficacy and safety of ProTrans, a treatment developed to protect insulin-producing cells, which in this study is being administered for the first time to children and adolescents with newly diagnosed type 1 diabetes.

The ProTrans-Young study is a double-blind, randomized, and placebo-controlled trial divided into two phases. In the first phase (Phase Ib), all patients, including those aged 7–18 years, were treated to ensure the safety of the treatment. The second phase (Phase IIb) includes a total of 60 children and adolescents, with 30 treated with ProTrans and 30 with placebo. The treatment of the first 30 patients aged 12–21 years has already been completed, and the safety data has been thoroughly reviewed and approved by the study’s safety committee.

The purpose of the ProTrans treatment is to halt the autoimmune destruction of insulin-producing cells in children and adolescents, slowing the disease progression and reduce the risk of serious complications associated with type 1 diabetes. The study aims to demonstrate that the treatment can preserve a greater portion of the body’s own insulin production, which would result in improved blood sugar regulation, reduced associated illnesses and thereby a better quality of life for the young patients.

For more information about the study and participation, please visit: NextCell Pharma - Study Information.

Professor Per-Ola Carlsson is the principal investigator for ProTrans-Young and the study is sponsored by Uppsala University. NextCell continues to contribute ProTrans, placebo, as well as support for logistics, documentation, and expert competence. The cells used for the production of ProTrans are of the same type as the cells that the subsidiary Cellaviva collects for family stem cell banking.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell is also a 100% owner of the daughter company, QVance which will offer quality control analytics for advanced therapy developers.

Download attachment Read full press release on Cision (external link)

2018-05-18

Six patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that an additional three patients have been treated with ProTrans in the ongoing clinical phase I/II trial. In total 6 patients with type 1 diabetes in the low- and medium-dose-cohort have now undergone treatment. The trial performed with NXTCL's drug candidate ProTrans, is divided into two parts, the first part being a dose-escalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now all patients in the low-dose-cohort and the medium-dose-cohort have been treated. After the 1-month follow-up of the

Read more Read more

2018-04-30

Today NextCell Publishes its half-year report

NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018) By "NextCell" or "Company" is meant NextCell Pharma AB with organization number 556965-8361. Amount in brackets in the report refers to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31. First half (2017-09-01 till 2018-02-28) · Net sales amounted to SEK 391 204 (120 594). · Operating result amounted to SEK -7 524 256 (-4 863 506). · Cash and bank amounted to SEK 9 444 381 (4 124 396). ·

Read more Read more

2018-04-27

NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.

NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and China, but is otherwise without claims or obligations and does not affect NextCell financially. NextCell has developed a patented applied for selection algorithm to ensure the selection and production of potent mesenchymal stem cells in

Read more Read more

2018-03-27

The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.

Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort. The Data and Safety Monitoring Boards consists of; Ulf Smith MD, PhD, Professor and Director, Lundberg Laboratory for Diabetes Research, Sahlgrenska Academy and Sahlgrenska University Hospital, Gothenburg; Anders Fasth MD, PhD, Professor of Pediatric Immunology, Sahlgrenska Academy and Chief Physician

Read more Read more

2018-03-14

An update on NextCell Pharma and Nordic Tech House

NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights. NextCell Pharma buys services from Nordic Tech House to increase exposure of NextCell Pharma and Cellaviva, both to inform about its development of stem cell therapies and stem cell saving and to optimize the digital messaging for the next 2 years. For its Nordic Tech House is paid with shares in NextCell Pharma AB through

Read more Read more

2018-03-14

Nordic Tech House to invest in stem cell company NextCell Pharma

NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the

Read more Read more

2018-03-06

NextCell CEO invited speaker at the Swedish National ATMP Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th. The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord. NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult

Read more Read more

2018-02-22

Three patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment. The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can start inclusion of patients in the

Read more Read more